Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Gruber, Leonhard [VerfasserIn]   i
 Decristoforo, Clemens [VerfasserIn]   i
 Uprimny, Christian [VerfasserIn]   i
 Hohenberger, Peter [VerfasserIn]   i
 Schönberg, Stefan [VerfasserIn]   i
 Orlandi, Francesca [VerfasserIn]   i
 Mariani, Maurizio Franco [VerfasserIn]   i
 Manzl, Claudia [VerfasserIn]   i
 Kasseroler, Maria Theresia [VerfasserIn]   i
 Tilg, Herbert [VerfasserIn]   i
 Zelger, Bettina [VerfasserIn]   i
 Jaschke, Werner [VerfasserIn]   i
 Virgolini, Irene J. [VerfasserIn]   i
Titel:Imaging properties and tumor targeting of 68Ga-NeoBOMB1, a gastrin-releasing peptide receptor antagonist, in GIST patients
Verf.angabe:Leonhard Gruber, Clemens Decristoforo, Christian Uprimny, Peter Hohenberger, Stefan O. Schoenberg, Francesca Orlandi, Maurizio Franco Mariani, Claudia Manzl, Maria Theresia Kasseroler, Herbert Tilg, Bettina Zelger, Werner R. Jaschke and Irene J. Virgolini
E-Jahr:2022
Jahr:11 November 2022
Umfang:13 S.
Fussnoten:Im Titel ist die Zahl 68 hochgestellt ; Gesehen am 18.01.2023
Titel Quelle:Enthalten in: Biomedicines
Ort Quelle:Basel : MDPI, 2013
Jahr Quelle:2022
Band/Heft Quelle:10(2022), 11, Artikel-ID 2899, Seite 1-13
ISSN Quelle:2227-9059
Abstract:Background: Gastrin-releasing peptide receptors (GRPRs) are molecular imaging targets in multiple malignancies. Recently, NeoBOMB1, a 68Ga-labelled antagonist to GRPRs, was developed for PET. Here we report the outcome of a Phase I/IIa clinical trial (EudraCT 2016-002053-38) describing diagnostic properties and covariates influencing uptake of 68Ga-NeoBOMB1 in oligometastatic gastrointestinal stromal tumor (GIST) patients. Methods: Nine patients with advanced GIST using PET/CT (computed tomography) were included. After kit-based 68Ga-NeoBOMB1 preparation with a licensed 68Ge/68Ga generator, 3 MBq/kg body weight were injected intravenously. PET/CT included dynamic and static PET scans 5, 12 and 18 min and 1, 2, and 3-4 h post injection (first six patients) and static PET scans 2 and 3-4 h post injection (last three participants). Tumor targeting was assessed on a per-lesion and per-patient basis. Results: Six patients showed visible radiotracer uptake in at least one tumor lesion. Seventeen out of 37 tumor lesions exhibited significant 68Ga-NeoBOMB1 uptake (median SUVmax 11.8 [range 2.8-51.1] 2 h p.i. and 13.2 [range 2.5-53.8] 3-4 h p.i) and improved lesion-to-background contrast over time. Five lesions (13.5%) were identified only by 68Ga-NeoBOMB1-PET, with no correlation on contrast-enhanced CT. Three patients showed no radiotracer accumulation in any lesions. Tracer uptake correlated with male sex (p < 0.0001), higher body mass index (p = 0.007), and non-necrotic lesion appearance (p = 0.018). There was no association with whole-lesion contrast enhancement, hepatic localization, mutational status, or disease duration. Conclusions: 68Ga-NeoBOMB1-PET exhibits variable tumor uptake in advanced-stage GIST patients, correlating with lesion vitality based on CT contrast uptake, opening the possibility of a theragnostic approach in selected cases.
DOI:doi:10.3390/biomedicines10112899
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

kostenfrei: Volltext: https://doi.org/10.3390/biomedicines10112899
 kostenfrei: Volltext: https://www.mdpi.com/2227-9059/10/11/2899
 DOI: https://doi.org/10.3390/biomedicines10112899
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:<sup>68</sup>Ga-NeoBOMB1
 GIST
 GRPR
 PET/CT
 phase IIa study
K10plus-PPN:1831336723
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69007647   QR-Code
zum Seitenanfang